Comparison of minipig, dog, monkey and human drug metabolism and disposition

Journal of Pharmacological and Toxicological Methods

Volumn 74, Issue , 2015, Pages 80-92

  Dalgaard, Lars ^a  

^a LD ADME Consult ^*  (Denmark)

Author keywords

Comparison; Development; Disposition; Dog; Drug; Metabolism; Methods; Monkey; Pig; Selection

Indexed keywords

3 PHOSPHOADENOSYL 5 PHOSPHOSULPHATE SULPHOTRANSFERASE; ACYLTRANSFERASE; ALDEHYDE OXIDASE; ATECEGATRAN METOXIL; CARRIER PROTEIN; CYTOCHROME; CYTOCHROME P450; DICENTRINE; FOSDEVIRINE; SULFOTRANSFERASE; UNCLASSIFIED DRUG; XIMELAGATRAN; DRUG;

ANALYTIC METHOD; COMPARATIVE STUDY; CONJUGATION; DOG; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; HAPLORHINI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MINIPIG; NONHUMAN; PRACTICE GUIDELINE; PROTEIN EXPRESSION; REVIEW; SPECIES DIFFERENCE; SULFATION; ANIMAL; BIOAVAILABILITY; DRUG INACTIVATION; METABOLISM; MOUSE; PHYSIOLOGY; PIG; PROCEDURES; TOXICITY TESTING;

ANIMALIA; CANIS FAMILIARIS; PRIMATES; RODENTIA; SUIDAE;

ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; HAPLORHINI; HUMANS; INACTIVATION, METABOLIC; MICE; PHARMACEUTICAL PREPARATIONS; SPECIES SPECIFICITY; SWINE; SWINE, MINIATURE; TOXICITY TESTS;

EID: 84937978842     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2014.12.005     Document Type: Review

References (121)

1. Alépée N., Bahinski T., Daneshian M., De Wever B., Fritsche E., Hansmann J., et al. Workshop report state-of-the-art of 3D cultures (Organs-on-a-Chip) in safety testing and pathophysiology - ALTEX Online first 2014, 1-42. Retrieved from http://dx.doi.org/10.14573/altex1406111.
2. Anzenbacher P., Soucek P., Anzenbacherová E., Gut I., Hrubý K., Svoboda Z., et al. Presence and activity of cytochrome P450 isofors in minipig liver microsomes: Comparison with human liver samples. Drug Metabolism and Disposition 1998, 26(1):56-59.
3. Bale S.S., Vernetti L., Senutovitch N., Jindal R., Hegde M., Gough A., et al. In vitro platforms for evaluating liver toxicity. Experimental Biology and Medicine (Maywood, N.J.) 2014, 239(9):1180-1191. 10.1177/1535370214531872.
4. Beasley V. Absorption, distribution, metabolism, and elimination[U+202F]: Differences among species (9-Aug-1999). Veterinary toxicology 1999, (p. www.ivis.org. Document No. A2659.0899.). V. Beasley (Ed.).
5. Behnia K., Bhatia S., Jastromb N., Balis U., Sullivan S., Yarmush M., et al. Xenobiotic metabolism by cultured primary porcine hepatocytes. Tissue Engineering 2000, 6(5):467-479. 10.1089/107632700750022125.
6. Bleasby K., Castle J.C., Roberts C.J., Cheng C., Bailey W.J., Sina J.F., et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006, 36(10-11):963-988. 10.1080/00498250600861751.
7. Blech S., Ebner T., Ludwig-schwellinger E., Stangier J., Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabolism and Disposition 2008, 36(2):386-399. 10.1124/dmd.107.019083.atrial.
8. Bode G., Clausing P., Gervais F., Loegsted J., Luft J., Nogues V., et al. The utility of the minipig as an animal model in regulatory toxicology. Journal of Pharmacological and Toxicological Methods 2010, 62(3):196-220. 10.1016/j.vascn.2010.05.009.
9. Bogaards J.J., Bertrand M., Jackson P., Oudshoorn M.J., Weaver R.J., van Bladeren P.J., et al. Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000, 30(12):1131-1152. 10.1080/00498250010021684.
10. Calabrese E.J. Comparative biology of test species. Environmental Health Perspectives 1988, 77:55-62. (Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1474542&tool=pmcentrez&rendertype=abstract).
11. Caldwell J. Conjugation reactions in foreign-compound metabolism: definition, consequences, and species variations. Drug Metabolism Reviews 1982, 13(5):745-777. 10.3109/03602538208991360.
12. Castellino S., Groseclose M.R., Sigafoos J., Wagner D., de Serres M., Polli J.W., et al. Central nervous system disposition and metabolism of Fosdevirine (GSK2248761), a non-nucleoside reverse transcriptase inhibitor: An LC-MS and matrix-assisted laser desorption/ionization imaging MS investigation into central nervous system toxicity. Chemical Research in Toxicology 2013, 26(2):241-251.
13. Cook D., Brown D., Alexander R., March R., Morgan P., Satterthwaite G., et al. Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nature Reviews Drug Discovery 2014, 13(6):419-431. (Retrieved from http://dx.doi.org/10.1038/nrd4309).
14. Dalgaard L., Larsen C. Metabolism and excretion of citalopram in man: Identification of O-acyl- and N-glucuronides. Xenobiotica 1999, 29(10):1033-1041.
15. Desille M., Corcos L., L'Helgoualc'h A., Frémond B., Campion J.-P., Guillouzo A., et al. Detoxifying activity in pig livers and hepatocytes intended for xenotherapy. Transplantation 1999, 68(10). (Retrieved from http://journals.lww.com/transplantjournal/Fulltext/1999/11270/DETOXIFYING_ACTIVITY_IN_PIG_LIVERS_AND_HEPATOCYTES.2.aspx).
16. Diaz G.J., Squires E.J. Role of aldehyde oxidase in the hepatic in vitro metabolism of 3-methylindole in pigs. Journal of Agricultural and Food Chemistry 2000, 48(3):833-837. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10725159).
17. Ebeling M., Küng E., See A., Broger C., Steiner G., Berrera M., et al. Genome-based analysis of the nonhuman primate Macaca fascicularis as a model for drug safety assessment. Genome Research 2011, 21(10):1746-1756. 10.1101/gr.123117.111.
18. Ellegaard L., Cunningham A., Edwards S., Grand N., Nevalainen T., Prescott M., et al. Welfare of the minipig with special reference to use in regulatory toxicology studies. Journal of Pharmacological and Toxicological Methods 2010, 62(3):167-183. 10.1016/j.vascn.2010.05.006.
19. Ennulat D., Walker D., Clemo F., Magid-Slav M., Ledieu D., Graham M., et al. Effects of hepatic drug-metabolizing enzyme induction on clinical pathology parameters in animals and man. Toxicologic Pathology 2010, 38(5):810-828. 10.1177/0192623310374332.
20. Felsted R.L., Chu a E., Chaykin S. Purification and properties of the aldehyde oxidases from hog and rabbit livers. The Journal of Biological Chemistry 1973, 248(7):2580-2587. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/4698232).
21. Gao H., Deng S., Obach R.S. A simple liquid chromatography-tandem mass spectrometry metabolites across species for metabolite safety assessments. Drug Metabolism and Disposition 2010, 38:2147-2156. 10.1124/dmd.110.034637.
22. Garattini E., Terao M. Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metabolism Reviews 2011, 43(3):374-386. 10.3109/03602532.2011.560606.
23. Garattini E., Terao M. The role of aldehyde oxidase in drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 2012, 8(4):487-503. 10.1517/17425255.2012.663352.
24. Garattini E., Terao M. Aldehyde oxidase and its importance in novel drug discovery: Present and future challenges. Expert Opinion on Drug Discovery 2013, 8(6):641-654. 10.1517/17460441.2013.788497.
25. Giacomini K.M., Huang S.-M. Transporters in drug development and clinical pharmacology. Clinical Pharmacology and Therapeutics 2013, 94(1):3-9. 10.1038/clpt.2013.86.
26. Giacomini K.M., Huang S.-M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., et al. Membrane transporters in drug development. Nature Reviews Drug Discovery 2010, 9(3):215-236.
27. Gillberg M., Skaanild M.T., Friis C. Regulation of gender-dependent CYP2A expression in pigs: Involvement of androgens and CAR. Basic & Clinical Pharmacology & Toxicology 2006, 98(5):480-487. 10.1111/j.1742-7843.2006.pto_261.x.
28. Godoy P., Hewitt N.J., Albrecht U., Andersen M.E., Ansari N., Bhattacharya S., et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology 2013, 87:1315-1530. 10.1007/s00204-013-1078-5.
29. Groenen M.a M., Archibald A.L., Uenishi H., Tuggle C.K., Takeuchi Y., Rothschild M.F., et al. Analyses of pig genomes provide insight into porcine demography and evolution. Nature 2012, 491(7424):393-398. 10.1038/nature11622.
30. Gruenewald S., Wahl B., Bittner F., Hungeling H., Kanzow S., Kotthaus J., et al. The fourth molybdenum containing enzyme mARC: Cloning and involvement in the activation of N-hydroxylated prodrugs. Journal of Medicinal Chemistry 2008, 51(24):8173-8177. 10.1021/jm8010417.
31. Hagos Y., Bahn A., Asif A.R., Krick W., Sendler M., Burckhardt G. Cloning of the pig renal organic anion transporter 1 (pOAT1). Biochimie 2002, 84(12):1221-1224. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12628298).
32. Hagos Y., Braun I.M., Krick W., Burckhardt G., Bahn A. Functional expression of pig renal organic anion transporter 3 (pOAT3). Biochimie 2005, 87:421-424.
33. Hamby-Mason R., Chen J.J., Schenker S., Perez A., Henderson G.I. Catalase mediates acetaldehyde formation from ethanol in fetal and neonatal rat brain. Alcoholism: Clinical and Experimental Research 1997, 21(6):1063-1072. 10.1111/j.1530-0277.1997.tb04255.x.
34. Havemeyer A., Grünewald S., Wahl B., Bittner F., Mendel R., Erdelyi P., et al. Short communication reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC. Drug Metabolism and Disposition 2010, 38(11):1917-1921. 10.1124/dmd.110.032813.amidoxime.
35. Havemeyer A., Lang J., Clement B. The fourth mammalian molybdenum enzyme mARC: Current state of research. Drug Metabolism Reviews 2011, 43(4):524-539. 10.3109/03602532.2011.608682.
36. Helke K.L., Swindle M.M. Animal models of toxicology testing: The role of pigs. Expert Opinion on Drug Metabolism & Toxicology 2013, 9(2):127-139. 10.1517/17425255.2013.739607.
37. Hengstler J.G., Van der Burg B., Steinberg P., Oesch F. Interspecies differences in cancer susceptibility and toxicity. Drug Metabolism Reviews 1999, 31(4):917-970. 10.1081/DMR-100101946.
38. Hosagrahara V.P., Hansen L.K., Remmel R.P. Induction of the metabolism of midazolam by rifampin in cultured porcine hepatocytes: Preliminary evidence for CYP3A isoforms in pigs. Drug Metabolism and Disposition 1999, 27(12):1512-1518.
39. Hvenegaard M.G., Bang-Andersen B., Pedersen H., Jørgensen M., Püschl A., Dalgaard L. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2012, 40(7):1357-1365. 10.1124/dmd.112.044610.
40. Jacobs A. Use of nontraditional animals for evaluation of pharmaceutical products. Expert Opinion on Drug Metabolism & Toxicology 2006, 2(3):345-349. 10.1517/17425255.2.3.345.
41. Kaivosaari S., Finel M., Koskinen M. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica 2011, 41(8):652-669. 10.3109/00498254.2011.563327.
42. Keisu M., Andersson T.B. Drug-induced liver injury in humans: The case of ximelagatran. Adverse Drug Reactions SE - 13 2010, Vol. 196:407-418. Springer, Berlin Heidelberg. 10.1007/978-3-642-00663-0_13. J. Uetrecht (Ed.).
43. Kitamura S., Tatsumi K. Reduction of tertiary amine n-oxides by liver preparations: Function of aldehyde oxidase as a major n-oxide reductase. Biochemical and Biophysical Research Communications 1984, 121(3):749-754.
44. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharmaceutical Research 2007, 24(7):1227-1251. 10.1007/s11095-007-9254-z.
45. Kraus T., Uttamsingh V., Anders M.W., Wolf S. Porcine kidney microsomal cysteine S-conjugate N-acetyltransferase-catalyzed N-acetylation of haloalkene-derived cysteine S-conjugates. Drug Metabolism and Disposition 2000, 28(4):440-445.
46. Lai Y. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opinion on Drug Metabolism & Toxicology 2009, 5(10):1175-1187. 10.1517/17425250903127234.
47. Lai Y.C., Kuo T., Chen C., Tsai H., Lee S. Metabolism of dicentrine: Identification of the phase I and phase II metabolites in miniature pig urine. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2010, 1714-1722. 10.1124/dmd.110.033795.
48. 14C-labeled drug and accelerator mass spectrometry. Bioanalysis 2010, 2(7):1315-1324. 10.4155/bio.10.87.
49. Lappin G., Seymour M., Gross G., Jørgensen M., Kall M., Kværnø L. Meeting the MIST regulations: Human metabolism in phase I using AMS and a tiered bioanalytical approach. Bioanalysis 2012, 4(4):407-416. 10.4155/bio.11.334.
50. Leblanc B., Jezequel S., Davies T., Hanton G., Taradach C. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regulatory Toxicology and Pharmacology: RTP 1998, 28(2):124-132. 10.1006/rtph.1998.1243.
51. Li M., Yuan H., Li N., Song G., Zheng Y., Baratta M., et al. Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2008, 35(1-2):114-126. 10.1016/j.ejps.2008.06.008.
52. Lieber C.S. Hepatic, metabolic and toxic effects of ethanol: 1991 update. Alcoholism: Clinical and Experimental Research 1991, 15(4):573-592. 10.1111/j.1530-0277.1991.tb00563.x.
53. Lootens L., Van Eenoo P., Meuleman P., Leroux-Roels G., Delbeke F.T. The uPA(+/+)-SCID mouse with humanized liver as a model for in vivo metabolism of 4-androstene-3,17-dione. Drug Metabolism and Disposition 2009, 37(12):2367-2374. 10.1124/dmd.109.028183.
54. Loureiro A.I., Fernandes-Lopes C., Bonifacio M.J., Wright L.C., Soares-da-Silva P. N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor. Drug Metabolism and Disposition 2013, 10.1124/dmd.113.053736.
55. Lower G.M., Nilsson T., Nelson C.E., Wolf H., Gamsky T.E., Bryan G.T. N-acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environmental Health Perspectives 1979, 29(April):71-79. 10.1093/ije/dyl290.
56. Lu C., Li a P. Species comparison in P450 induction: Effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chemico-Biological Interactions 2001, 134(3):271-281. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11336975.
57. Madden S., Gentile D.M., Crawford G.A., Simpson A.G., Johnston A.M. Cytochrome P450 activities in hepatic microsomes from the mini pig. ISSX Proc 1998, Vol. 13:73.
58. Maronpot R.R., Yoshizawa K., Nyska A., Harada T., Flake G., Mueller G., et al. Hepatic enzyme induction: Histopathology. Toxicologic Pathology 2010, 38(5):776-795. 10.1177/0192623310373778.
59. Matsson E.M., Eriksson U.G., Palm J.E., Artursson P., Karlgren M., Lazorova L., et al. Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor. Molecular Pharmaceutics 2013, 10(11):4252-4262. 10.1021/mp400341t.
60. Matsson E.M., Palm J.E., Eriksson U.G., Bottner P., Lundahl A., Knutson L., et al. Effects of ketoconazole on the in vivo biotransformation and hepatobiliary transport of the thrombin inhibitor AZD0837 in pigs. Drug Metabolism and Disposition 2011, 39(2):239-246. 10.1124/dmd.110.035022.the.
61. McAnulty P.A., Dayan A.D., Ganderup N.-C., Hastings K.L. The minipig in biomedical research 2011, CRC Press.
62. Miyajima M., Kusuhara H., Fujishima M., Adachi Y., Sugiyama Y. Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood-brain barrier in mice. Drug Metabolism and Disposition 2011, 39(5):814-819. 10.1124/dmd.110.036863.the.
63. Monshouwer M., Van't Klooster G.a, Nijmeijer S.M., Witkamp R.F., van Miert a S. Characterization of cytochrome P450 isoenzymes in primary cultures of pig hepatocytes. Toxicology in Vitro: An International Journal Published in Association with BIBRA 1998, 12(6):715-723. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20654461).
64. Myers M.J., Farrell D.E., Howard K.D., Kawalek J.C. Identification of multiple constitutive and inducible hepatic cytochrome P450 enzymes in market weight swine. Drug Metabolism and Disposition 2001, 29(6):908-915.
65. Nakayama S., Atsumi R., Takakusa H., Kobayashi Y., Kurihara A., Nagai Y., et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding 2009, 37(9):1970-1977. 10.1124/dmd.109.027797.binding.
66. Nebbia C., Dacasto M., Rossetto Giaccherino a, Giuliano Albo a, Carletti M. Comparative expression of liver cytochrome P450-dependent monooxygenases in the horse and in other agricultural and laboratory species. The Veterinary Journal 2003, 165(1):53-64. 10.1016/S1090-0233(02)00174-0.
67. Nielsen P., Dalgaard L. A sulphate metabolite of trimethoprim in goats and pigs. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 1978, 8(11):657-664.
68. Obach R.S., Nedderman A.N., Smith D.a. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: Are they still necessary?. Xenobiotica 2012, 42(1):46-56. 10.3109/00498254.2011.621985.
69. Oshino N., Oshino R., Chance B. The characteristics of the "peroxidatic" reaction of catalase in ethanol oxidation. The Biochemical Journal 1973, 131(3):555-563. (Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1177502&tool=pmcentrez&rendertype=abstract).
70. Padda M.S., Sanchez M., Akhtar A.J., Boyer J.L. Drug-induced cholestasis. Hepatology 2011, 53(4):1377-1387. 10.1002/hep.24229.
71. Parkinson A., Ogilvie B.W. Biotransformation of xenobiotics. Cassaret & Doull's Toxicology: The basic science of poisons 2008, 161-304. McGraw-Hill Book Co. 7th ed. C.D. Klaassen (Ed.).
72. Patabendige A., Abbott N.J. Primary porcine brain microvessel endothelial cell isolation and culture. Current protocols in neuroscience 2014, John Wiley & Sons, Inc. 10.1002/0471142301.ns0327s69.
73. Patabendige A., Skinner R.A., Abbott N.J. Establishment of a simplified in vitro porcine blood-brain barrier model with high transendothelial electrical resistance. Brain Research 2013, 1521:1-15. 10.1016/j.brainres.2012.06.057.
74. Patabendige A., Skinner R.A., Morgan L., Abbott N.Joan A detailed method for preparation of a functional and flexible blood-brain barrier model using porcine brain endothelial cells. Brain Research 2013, 1521(100):16-30. 10.1016/j.brainres.2013.04.006.
75. Pellegatti M. Preclinical in vivo ADME studies in drug development: A critical review. Expert Opinion on Drug Metabolism & Toxicology 2012, 8(2):161-172. 10.1517/17425255.2012.652084.
76. Persson M., Løye A.F., Mow T., Hornberg J.J. A high content screening assay to predict human drug-induced liver injury during drug discovery. Journal of Pharmacological and Toxicological Methods 2013, 68(3):302-313. 10.1016/j.vascn.2013.08.001.
77. Preusse C., Skaanild M.T. Pharmacology and ADME studies in the minipig. The minipig in biomedical research 2011, 141-142. CRC Press.
78. Pryde D.C., Dalvie D., Hu Q., Jones P., Obach R.S., Tran T.-D. Aldehyde oxidase: An enzyme of emerging importance in drug discovery. Journal of Medicinal Chemistry 2010, 53(24):8441-8460. 10.1021/jm100888d.
79. Puccinelli E., Gervasi P.G., Longo V. Xenobiotic metabolizing cytochrome P450 in pig, a promising animal model. Current Drug Metabolism 2011, 12(6):507-525. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21476973).
80. Rizwan A.N., Burckhardt G. Organic anion transporters of the SLC22 family: Biopharmaceutical, physiological, and pathological roles. Pharmaceutical Research 2007, 24(3):450-470. 10.1007/s11095-006-9181-4.
81. Roffey S.J., Obach R.S., Gedge J.I., Smith D.a. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metabolism Reviews 2007, 39(1):17-43. 10.1080/03602530600952172.
82. Scheer N., Wolf C.R. Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications. Xenobiotica 2013, 8254:1-13. 10.3109/00498254.2013.815831.
83. Sekine T., Miyazaki H., Endou H. Molecular physiology of renal organic anion transporters. American Journal of Physiology. Renal Physiology 2006, 290(2):F251-F261. 10.1152/ajprenal.00439.2004.
84. Sharer J.E., Shipley L.A., Vandenbranden M.R., Binkley S.N., Wrighton S.A. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition 1995, 23(11):1231-1241. (Retrieved from http://ukpmc.ac.uk/abstract/MED/8591724).
85. Shimada T., Mimura M., Inoue K., Nakamura S., Oda H., Ohmori S., et al. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Archives of Toxicology 1997, 71(6):401-408. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9195021).
86. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. The Journal of Pharmacology and Experimental Therapeutics 1994, 270(1):414-423. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8035341).
87. Sjödin E., Fritsch H., Eriksson U.G., Logren U., Nordgren A., Forsell P., et al. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs 2008, 36(8):1519-1528. 10.1124/dmd.108.020412.functions.
88. Sjögren E., Bredberg U., Allard E., Arvidsson B., Bergquist J., Andersson T.B., et al. Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model. Pharmaceutical Research 2010, 27(4):597-607. 10.1007/s11095-009-0016-y.
89. Sjögren E., Bredberg U., Lennernäs H. The pharmacokinetics and hepatic disposition of repaglinide in pigs: Mechanistic modeling of metabolism and transport. Molecular Pharmaceutics 2012, 9(4):823-841. 10.1021/mp200218p.
90. Skaanild M.T., Friis C. Cytochrome P450 sex differences in minipigs and conventional pigs. Pharmacology & Toxicology 1999, 85(4):174-180. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10563516).
91. Skaanild M.T., Friis C. Is cytochrome P450 CYP2D activity present in pig liver?. Pharmacology & Toxicology 2002, 91(4):198-203. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12530471).
92. Skaanild M.T., Friis C. Is bupropion a more specific substrate for porcine CYP2E than chlorzoxazone and p-nitrophenol?. Basic & Clinical Pharmacology & Toxicology 2007, 101(3):159-162. 10.1111/j.1742-7843.2007.00083.x.
93. Smith D.a, Obach R.S. Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chemical Research in Toxicology 2009, 22(2):267-279. 10.1021/tx800415j.
94. Stepan A.F., Walker D.P., Bauman J., Price D.A., Baillie T.A., Kalgutkar A.S., et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chemical Research in Toxicology 2011, 24(9):1345-1410. 10.1021/tx200168d.
95. Stevens J.C., Shipley L.A., Cashman J.R., Vandenbranden M., Wrighton S.A. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metabolism and Disposition 1993, 21(5):753-760. (Retrieved from http://dmd.aspetjournals.org/content/21/5/753.abstract).
96. Suenderhauf C., Parrott N. A physiologically based pharmacokinetic model of the minipig: Data compilation and model implementation. Pharmaceutical Research 2013, 30(1):1-15. 10.1007/s11095-012-0911-5.
97. Syvänen S., Lindhe Ö., Palner M., Kornum B.R., Rahman O., Långström B., et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metabolism and Disposition 2009, 37(3):635-643. 10.1124/dmd.108.024745.of.
98. Tahara H., Kusuhara H., Chida M., Fuse E., Sugiyama Y. Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance ? Effect of probenecid on the renal elimination of H2 receptor antagonists. The Journal of Pharmacology and Experimental Therapeutics 2006, 316(3):1187-1194. 10.1124/jpet.105.094052.2004.
99. Tahara H., Shono M., Kusuhara H., Kinoshita H., Fuse E., Takadate A., et al. Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharmaceutical Research 2005, 22(4):647-660. 10.1007/s11095-005-2503-0.
100. Terao M., Kurosaki M., Barzago M.M., Varasano E., Boldetti A., Bastone A., et al. Avian and canine aldehyde oxidases. Novel insights into the biology and evolution of molybdo-flavoenzymes. The Journal of Biological Chemistry 2006, 281(28):19748-19761. 10.1074/jbc.M600850200.
101. Thompson R.a, Isin E.M., Li Y., Weidolf L., Page K., Wilson I., et al. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chemical Research in Toxicology 2012, 25(8):1616-1632. 10.1021/tx300091x.
102. Thörn H.A., Lundahl A., Schrickx J.A., Dickinson P.A., Lennernäs H. Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2011, 43:89-98.
103. Trepanier L.a, Ray K., Winand N.J., Spielberg S.P., Cribb a E. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochemical Pharmacology 1997, 54(1):73-80. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9296352).
104. Turpeinen M., Ghiciuc C., Opritoui M., Tursas L., Pelkonen O., Pasanen M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative study in vitro. Xenobiotica 2007, 37(12):1367-1377. 10.1080/00498250701658312.
105. Uno Y., Iwasaki K., Yamazaki H., Nelson D.R. Macaque cytochromes P450: Nomenclature, transcript, gene, genomic structure, and function. Drug Metabolism Reviews 2011, 43(3):346-361. 10.3109/03602532.2010.549492.
106. Uno Y., Kumano T., Kito G., Nagata R., Kamataki T., Fujino H. CYP2C76-mediated species difference in drug metabolism: A comparison of pitavastatin metabolism between monkeys and humans. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 2007, 37(1):30-43. 10.1080/00498250600968275.
107. Vamathevan J.J., Hall M.D., Hasan S., Woollard P.M., Xu M., Yang Y., et al. Minipig and beagle animal model genomes aid species selection in pharmaceutical discovery and development. Toxicology and Applied Pharmacology 2013, 270(2):149-157. 10.1016/j.taap.2013.04.007.
108. Van der Laan J.W., Brightwell J., McAnulty P., Ratky J., Stark C. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. Journal of Pharmacological and Toxicological Methods 2010, 62(3):184-195. 10.1016/j.vascn.2010.05.005.
109. Van Peer E., Verbueken E., Saad M., Casteleyn C., Van Ginneken C., Van Cruchten S. Ontogeny of CYP3A and P-glycoprotein in the liver and the small intestine of the Goettingen minipig: An immunohistochemical evaluation. Basic & Clinical Pharmacology & Toxicology 2014, 114(5):387-394. 10.1111/bcpt.12173.
110. Webster J., Bollen P., Grimm H., Jennings M. Ethical implications of using the minipig in regulatory toxicology studies. Journal of Pharmacological and Toxicological Methods 2010, 62(3):160-166. 10.1016/j.vascn.2010.05.002.
111. Yan Z., Lu C., Wu J.-T., Elvebak L., Brockman A. Validation of a high-throughput absorption, distribution, metabolism, and excretion (ADME) system and results for 60 literature compounds. Rapid Communications in Mass Spectrometry 2005, 19(9):1191-1199. 10.1002/rcm.1903.
112. Yu Y., Liu X., Zhang Z., Xiao Y., Hong M. Cloning and functional characterization of the pig (Sus scrofa) organic anion transporting polypeptide 1a2. Xenobiotica 2013, 43(8):738-744. 10.3109/00498254.2012.760762.
113. Zhang Z., Schwartz S., Wagner L., Miller W. A greedy algorithm for aligning DNA sequences. Journal of Computational Biology: A Journal of Computational Molecular Cell Biology 2000, 7(1-2):203-214. 10.1089/10665270050081478.
114. EMA Guideline on the investigation of drug interactions http://www.ema.europa.eu.
115. FDA Safety testing of drug metabolites ([Electronic version]). http://www.fda.gov.
116. FDA DDI draft guideline Drug interaction studies - Study design, data analysis, implications for dosing, and labeling recommendations ([Electronic version]. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
117. ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals ([Electronic version]. Available: www.ich.org/products/guidelines/safety. http://www.emea.europa.eu.
118. ICH M3 (R2) Questions and Answers http://www.ich.org/products/guidelines/multidisciplinary/multidisciplinary-single/article/questions-answers-guidance-on-non-clinical-safety-studies-for-the-conduct-of-human-clinical-trial.html.
119. ICH S3A http://www.ich.org/products/guidelines/safety/safety-single/article/note-for-guidance-on-toxicokinetics-the-assessment-of-systemic-exposure-in-toxicity-studies.html.
120. ICH S3B http://www.ich.org/products/guidelines/safety/safety-single/article/note-for-guidance-on-toxicokinetics-the-assessment-of-systemic-exposure-in-toxicity-studies.html.
121. NCBI http://blast.ncbi.nlm.nih.gov/Blast.cgi.